TTFields + paclitaxel

TTFields + paclitaxel is a **combination therapy** consisting of Tumor Treating Fields (TTFields) and the chemotherapeutic agent paclitaxel. TTFields is a noninvasive, locoregional cancer therapy delivered via wearable transducer arrays that emit low-intensity, intermediate-frequency alternating electric fields designed to disrupt cancer cell division primarily during mitosis, leading to apoptosis and cell death[1][4]. Paclitaxel is a microtubule stabilizer that inhibits tumor cell mitosis by binding to tubulin and promoting polymerization, resulting in mitotic arrest and apoptosis. The combination is under clinical investigation, notably in recurrent ovarian cancer, where early-phase data from the INNOVATE trial and preclinical studies suggest synergistic antitumoral effects, improved progression-free survival, and safety[1][4]. Paclitaxel is administered weekly (commonly intravenous). TTFields are delivered via proprietary medical devices, typically produced by Novocure, and worn for extended periods each day. This combination is specifically for recurrent ovarian cancer and being evaluated as a potential first-line option for this indication[4].

Brand names

TTFields + paclitaxel

Other names

TTFields plus paclitaxelTumor Treating Fields + paclitaxel